Peter heads DMPK operations at Grey Wolf Therapeutics. Previously director of DMPK at Vertex Pharmaceuticals, Peter is the current head of DMPK, in vivo pharmacology and head of preclinical studies at Ryvu Therapeutics. He is also part of the clinical team for DMPK and clinical pharmacology as well as being part of the site research leadership team.
Peter has worked on many projects covering multiple therapeutics areas with a specialism in human PK and dose prediction. He has provided dose predictions for several drugs on the market with more currently going through clinical trials.
Peter obtained his PhD from The University of Leicester looking at electrochemical quartz crystal microbalance studies to investigate optimum physicochemical properties of molecules required to penetrate leaf cuticles.